This document outlines the use of saliva as a diagnostic sample for detecting SARS-CoV-2 infection, considering the advantages, limitations and uncertainties associated with the use of saliva as sample material.
These report presents the results of the EQA on antimicrobial susceptibility testing (AST) for national public health laboratories for Campylobacter within the Food‐ and Waterborne Diseases and Zoonoses Network (FWD-Net).
This report presents the objectives, methods, results, and conclusions of a collaborative study called the 'European Listeria Typing Exercise’ (ELiTE), as well as recommendations for further studies.
A collaborative study between ECDC, the European Food Safety Authority (EFSA) and the European Union Reference Laboratory (EURL) for Listeria monocytogenes* found a relatively high degree of dissemination of certain listeriosis bacteria in the food chain and in the human population across the European Union (EU).
Between May 2018 and December 2020, 193 human cases of Salmonella Enteritidis sequence type (ST)11 were reported in Denmark (2), Finland (4), France (33), Germany (6), Ireland (12), the Netherlands (3), Poland (5), Sweden (6), and the United Kingdom (UK) (122). One in five cases was hospitalised. One death was reported. Fifty percent of the cases were children ≤ 18 years. The most recent case was reported by the UK in December 2020.
ECDC has mapped the detection and characterisation capability and capacity for SARS-CoV-2 variants across the EU/EEA. This is the fifth laboratory capacity survey since the beginning of the COVID-19 pandemic in December 2019.
This document provides laboratories with a single protocol for producing recombinant full-length hamster prion protein and using it to perform the Real-Time Quaking-Induced Conversion assay (RT-QuIC), which can distinguish sporadic Creutzfeldt-Jakob disease (sCJD) from variant Creutzfeldt-Jakob disease (vCJD).
This report assesses the current status of the EU/EEA and the UK COVID-19 laboratory response based on a short survey sent to all Member States and the UK.
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on which technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance.